Indivior Pharmaceuticals (INDV) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Travere Therapeutics (TVTX) has outperformed Indivior Pharmaceuticals (INDV) over the past year, gaining 98.6% versus a gain of 47.3%. Over five years, INDV leads with a +123.7% price change compared with +112.4% for TVTX. Travere Therapeutics is the larger company by market cap ($4.91 billion vs $4.18 billion), about 1.2 times the size.
On valuation, Indivior Pharmaceuticals trades at a lower forward P/E (7.3x vs 9.2x for Travere Therapeutics). Indivior Pharmaceuticals converts more of its revenue into profit, with a net margin of 16.9% versus -5.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INDV | TVTX |
|---|---|---|
| Share price | $35.45 | $52.04 |
| Market cap | $4.18B | $4.91B |
| 1-day change | -1.88% | -2.62% |
| YTD return | -1.20% | +36.19% |
| 1-year return | +47.28% | +98.63% |
| 5-year return | +123.66% | +112.41% |
| P/E ratio (TTM) | 12.71 | — |
| Forward P/E | 7.26 | 9.23 |
| EPS (TTM) | $2.79 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.24B | $490.73M |
| Revenue growth (YoY) | +4.29% | +110.45% |
| Net income (latest FY) | $210.00M | $-25.55M |
| Gross margin | 80.23% | 97.89% |
| Operating margin | 21.15% | -12.80% |
| Net margin | 16.95% | -5.21% |
| 52-week high | $42.81 | $68.73 |
| 52-week low | $22.95 | $22.59 |
| Distance from 52-week high | -17.19% | -24.28% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +38.22% | +44.52% |
| Average volume | 2.08M | 1.59M |
| Shares outstanding | 118.03M | 94.26M |
| Employees | 827 | 497 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TVTX has outperformed INDV by 51.3 percentage points over the past year.
- Indivior Pharmaceuticals is more profitable, keeping 16.9 cents of every revenue dollar as net income versus -5.2 cents for Travere Therapeutics.
- Travere Therapeutics grew revenue faster in its latest fiscal year (+110.45% vs +4.29%).
- The two companies sit in different sectors: Indivior Pharmaceuticals in Health Care and Travere Therapeutics in Healthcare.
About Indivior Pharmaceuticals
INDV stock →Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Healthcare · Biotechnology · 497 employees
INDV vs TVTX FAQ
Which is bigger, Indivior Pharmaceuticals or Travere Therapeutics?
Travere Therapeutics (TVTX) is larger, with a market capitalization of $4.91B compared with $4.18B for Indivior Pharmaceuticals (INDV).
Which stock has performed better over the past year, INDV or TVTX?
TVTX returned +98.63% over the past 12 months, compared with +47.28% for INDV (price return, excluding dividends). Past performance does not predict future results.
Are Indivior Pharmaceuticals and Travere Therapeutics in the same industry?
No. Indivior Pharmaceuticals is in the Health Care sector, while Travere Therapeutics is in Healthcare.